Development of an Alzheimer's disease and cancer diagnostic system using Magtration technology (magnetic particle separation)
First written in FY2021. 3 of 4 entries say "Reframed", first in FY2023. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025ReframedAnnual report
「We are developing BIST (pronounced “Bist”), a measurement tool whose key feature is the simultaneous detection of multiple reactions, and have confirmed that GlycoBIST can be used as a simple quantification technology for glycans.」
The focus shifted from a diagnostic concept centered on Magtridge for Alzheimer’s disease and cancer to one that places glycan analysis and kidney disease diagnostic systems using GlycoBIST and LuBEA at the forefront as priority themes. - FY2024ReframedAnnual report
「We have also begun developing an automated instrument for the specific separation of immune cells using magnetic beads, in combination with the Swing Magtridge System, which was conceived as an enhanced and improved technology based on our proprietary Magtration® Technology.」
The description of the priority development focus changed from the original Magtridge concept centered on Alzheimer’s disease and cancer diagnostic systems to an automated instrument for separating immune cells, combining the Swing Magtridge System with an electrode chip. - FY2023ReframedAnnual report
「The most recent “three priority development themes for commercialization using our proprietary technologies” are as follows. “We will begin developing ‘Magtridge,’ an enhanced and improved version of the Magtration® technology, which has a proven track record in DNA/RNA (nucleic acid) extraction and immunoassay systems, for concentrating and purifying the relevant substances in blood and other samples.”」
The Magtridge development theme for Alzheimer’s disease and cancer diagnostic systems was positioned as one of the three priority development themes for commercialization, rather than remaining a standalone concept. The scope has also expanded to elemental technology development, including immune-cell and glycan recovery. - FY2021First statedAnnual report
「We will begin developing “Magtridge,” an enhanced and improved version of the Magtration® technology, which has a proven track record in DNA extraction and immunoassay systems, for concentrating and purifying the relevant substances in blood and other samples. We aim to realize an extraction and purification system for trace amounts of glycoproteins, cells, exosomes and other substances that were difficult to handle with conventional technologies. Development will proceed with the specific goals of building ① an Alzheimer’s disease diagnostic system and ② a cancer diagnostic system.」
A new R&D theme was presented that aims to extract and purify trace substances using Magtridge, an extension of Magtration technology, and build diagnostic systems for Alzheimer’s disease and cancer.